Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. WAT
WAT logo

WAT Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
346.540
Open
337.620
VWAP
342.70
Vol
235.78K
Mkt Cap
32.95B
Low
336.340
Amount
80.80M
EV/EBITDA(TTM)
33.44
Total Shares
98.17M
EV
33.77B
EV/OCF(TTM)
51.74
P/S(TTM)
6.33
Waters Corporation is a global life sciences and diagnostics company. The Company offers analytical instruments, separations technologies, and software, serving life, materials, food, and environmental sciences. Its segments include Waters and TA. The Company primarily designs, manufactures, sells and services high-performance liquid chromatography (HPLC), ultra-performance liquid chromatography (UPLC and together with HPLC, referred to as LC) and mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products and comprehensive post-warranty service plans. The Company designs, manufactures, sells and services thermal analysis, rheometry and calorimetry instruments through its TA Instruments (TA) product line. The Company is also a developer and supplier of advanced software-based products that interface with the Company’s instruments, as well as other manufacturers’ instruments.
Show More

Events Timeline

(ET)
2026-04-08
08:10:00
Waters Receives FDA Approval for Onclarity HPV Self-Collection Kit
select

News

PRnewswire
9.5
04-20PRnewswire
PinnedWaters Corporation to Hold Q1 2026 Earnings Call on May 5
  • Earnings Call Schedule: Waters Corporation will hold its Q1 2026 financial results conference call on May 5, 2026, at 8:30 a.m. Eastern Time, aimed at updating investors on the company's financial performance and outlook.
  • Live Webcast Availability: The presentation will be available via live webcast on Waters' Investor Relations website, ensuring that global investors can access real-time financial information, thereby enhancing transparency and investor confidence.
  • Replay Service: A replay of the webcast will be available until June 2, 2026, at midnight Eastern Time, allowing investors who cannot attend the live event to review the information, further improving accessibility to critical updates.
  • Company Background: Waters Corporation is a global leader in life sciences and diagnostics, dedicated to accelerating scientific innovation through analytical technologies and informatics, showcasing its significant role in ensuring the release of high-quality medicines and food and water safety.
PRnewswire
5.0
04-14PRnewswire
Waters Launches omniDAWN™ Multi-Angle Light Scattering Photometer
  • Technological Innovation: Waters Corporation's omniDAWN™ Multi-Angle Light Scattering Photometer features 18 detection angles, marking the first extended-range MALS detector for UHPLC and UPLC workflows, enabling size measurements from 50 nm to 500 nm, significantly enhancing the characterization of complex analytes.
  • Efficiency Boost: When paired with UHPLC or UPLC systems, the photometer supports run times up to four times faster than conventional HPLC workflows, while reducing sample consumption by 30-50% and solvent use by approximately 40%, thereby improving laboratory efficiency and resource utilization.
  • Data Quality Enhancement: The low dispersion design of the omniDAWN photometer preserves resolution and sensitivity, allowing for clearer differentiation between monomers, aggregates, and fragments, which supports scientists in making more informed decisions during drug discovery and development, accelerating the development of next-generation therapies.
  • Software Integration: Powered by ASTRA™ Software, the device integrates MALS with UV and RI detection to enable comprehensive analysis of size, composition, and heterogeneity in a single run, compliant with 21 CFR Part 11 and EU Annex 11, and is expected to be available globally in summer 2026.
seekingalpha
8.5
04-08seekingalpha
Waters Corporation Launches At-Home Cervical Cancer Screening Tool
  • FDA Approval for Self-Testing: The U.S. FDA has cleared Waters Corporation's Onclarity HPV Self-Collection Kit, which integrates with BD's Onclarity HPV Assay, aimed at enhancing accessibility and convenience for cervical cancer screening.
  • High-Risk HPV Detection: The Onclarity HPV Assay detects all high-risk cancer-causing HPV genotypes and was approved by the FDA in 2024 for self-collection screening in healthcare settings, marking a significant advancement in cervical cancer prevention.
  • Convenient Sample Processing: After collecting a cervical tissue sample, customers can mail the kit to a laboratory for processing, with results sent to their healthcare provider for follow-up, thereby improving screening efficiency.
  • Strong Market Potential: Waters Corporation announced that the Onclarity HPV Self-Collection Kit will be available by prescription in the coming months, which is expected to drive growth in the cervical cancer screening market and further solidify its leadership in biosciences and diagnostic solutions.
NASDAQ.COM
8.5
04-08NASDAQ.COM
Waters Receives FDA Clearance for HPV Self-Collection Kit
  • FDA Approval for Self-Collection Kit: Waters announced that its Onclarity HPV Self-Collection Kit has received FDA clearance, and when used with the BD Onclarity HPV Assay, it becomes the only FDA-approved HPV assay capable of identifying six individual results and three pooled results, enhancing accessibility for at-home testing.
  • Nationwide Partnerships: The company is establishing partnerships to ensure nationwide availability of the Onclarity HPV Self-Collection Kit, which is expected to be available by prescription in the coming months, further facilitating convenient home health management.
  • Automated Processing System: Samples will be processed on the fully automated BD COR System, which not only increases testing efficiency but also ensures result accuracy, thereby boosting consumer confidence in home self-testing.
  • Positive Market Reaction: In pre-market trading on the NYSE, Waters shares rose by 2% to $313.53, reflecting market optimism regarding the launch of the new product and its potential market impact.
PRnewswire
8.5
04-08PRnewswire
Waters Corporation Launches At-Home HPV Self-Collection Kit
  • FDA Approval Milestone: The FDA's clearance of Waters Corporation's Onclarity HPV Self-Collection Kit marks a significant milestone in expanding cervical cancer screening, expected to significantly increase screening rates and reduce the proportion of unscreened individuals, thereby lowering cervical cancer mortality.
  • Comprehensive HPV Detection: The kit, tested with the BD Onclarity HPV Assay, detects all high-risk HPV genotypes, providing the most comprehensive screening solution available, which helps clinicians identify risks earlier and intervene sooner, improving patient health outcomes.
  • Convenient Home Screening: The self-collection kit can be mailed directly to patients' homes via prescription, allowing them to collect samples at their convenience and send them back to the lab, which is expected to enhance accessibility to screening, especially for those unable to undergo regular screenings for various reasons.
  • Promoting Health Equity: Waters Corporation aims to promote health equity through this innovative tool, with plans to establish partnerships for broader nationwide access, ultimately reducing the burden of cervical cancer on women and individuals with a cervix.
Newsfilter
8.5
04-08Newsfilter
Waters Corporation Launches HPV Self-Collection Tool
  • FDA Approval: Waters Corporation announced that its Onclarity HPV Self-Collection Kit has received FDA clearance, marking a significant milestone in expanding cervical cancer screening in the U.S., which is expected to significantly increase screening rates and reduce cervical cancer risk.
  • Increased Convenience: The kit allows patients to collect samples at home, addressing barriers faced by approximately 60% of unscreened or under-screened individuals, thereby promoting early detection and intervention, which enhances public health outcomes.
  • Comprehensive Screening Capability: The Onclarity HPV Assay detects all high-risk HPV genotypes, making it the most comprehensive HPV screening tool available in the U.S. market, which is expected to improve clinicians' assessments of patient risks and subsequent care decisions.
  • Nationwide Partnerships: Waters is establishing partnerships to enable the self-collection kit to be available by prescription in the coming months, expected to be covered by insurance, further promoting health equity and facilitating earlier detection.
Wall Street analysts forecast WAT stock price to rise
13 Analyst Rating
Wall Street analysts forecast WAT stock price to rise
8 Buy
5 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
350.00
Averages
414.08
High
480.00
Current: 0.000
sliders
Low
350.00
Averages
414.08
High
480.00
UBS
Lu Li
Neutral
downgrade
$370 -> $330
AI Analysis
2026-04-13
Reason
UBS
Lu Li
Price Target
$370 -> $330
AI Analysis
2026-04-13
downgrade
Neutral
Reason
UBS analyst Lu Li lowered the firm's price target on Waters to $330 from $370 and keeps a Neutral rating on the shares. The firm updated the company's model.
Evercore ISI
Vijay Kumar
In Line -> Outperform
upgrade
$350
2026-04-06
Reason
Evercore ISI
Vijay Kumar
Price Target
$350
2026-04-06
upgrade
In Line -> Outperform
Reason
Evercore ISI analyst Vijay Kumar upgraded Waters to Outperform from In Line with a $350 price target. The firm believes Q1 numbers are "achievable" and a second half ramp "provides a nice backdrop for a comeback," the analyst tells investors.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for WAT
Unlock Now

Valuation Metrics

The current forward P/E ratio for Waters Corp (WAT.N) is 22.78, compared to its 5-year average forward P/E of 26.56. For a more detailed relative valuation and DCF analysis to assess Waters Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
26.56
Current PE
22.78
Overvalued PE
30.71
Undervalued PE
22.41

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
19.35
Current EV/EBITDA
13.00
Overvalued EV/EBITDA
22.40
Undervalued EV/EBITDA
16.29

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
6.39
Current PS
4.65
Overvalued PS
7.47
Undervalued PS
5.30

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

highest return likely tomorrow
Intellectia · 67 candidates
Market Cap: >= 300.00MPrice: $2.00 - $500.00One Day Rise Prob: >= 55One Day Predict Return: >= 3.0%Monthly Average Dollar Volume: >= 300,000
Ticker
Name
Market Cap$
top bottom
PL logo
PL
Planet Labs PBC
9.24B
BTSG logo
BTSG
Brightspring Health Services Inc
8.09B
RDW logo
RDW
Redwire Corp
1.94B
SY logo
SY
So-Young International Inc
332.79M
SNCY logo
SNCY
Sun Country Airlines Holdings Inc
874.99M
CLS logo
CLS
Celestica Inc
32.42B
which stock is going to skyrocket tomorrow
Intellectia · 41 candidates
Rsi Category: moderateRelative Vol: >= 1.20Analyst Action: UpgradeMoving Average Relationship: PriceCrossAboveMA20
Ticker
Name
Market Cap$
top bottom
BMA logo
BMA
Banco Macro SA
6.27B
HRI logo
HRI
Herc Holdings Inc
5.48B
CINT logo
CINT
Ci&T Inc
608.04M
RNGR logo
RNGR
Ranger Energy Services Inc
354.89M
RXRX logo
RXRX
Recursion Pharmaceuticals Inc
2.40B
LTH logo
LTH
Life Time Group Holdings Inc
6.15B

Whales Holding WAT

O
Oversea-Chinese Banking Corporation Limited
Holding
WAT
+66.97%
3M Return
R
RobecoSAM AG
Holding
WAT
+19.17%
3M Return
F
Freemont Capital Pte. Ltd.
Holding
WAT
+9.26%
3M Return
L
Logan Capital Management, Inc.
Holding
WAT
+6.03%
3M Return
M
Motley Fool Asset Management, LLC
Holding
WAT
+5.97%
3M Return
K
Kovitz Investment Group Partners, LLC
Holding
WAT
+5.89%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Waters Corp (WAT) stock price today?

The current price of WAT is 345.205 USD — it has increased 2.86

What is Waters Corp (WAT)'s business?

Waters Corporation is a global life sciences and diagnostics company. The Company offers analytical instruments, separations technologies, and software, serving life, materials, food, and environmental sciences. Its segments include Waters and TA. The Company primarily designs, manufactures, sells and services high-performance liquid chromatography (HPLC), ultra-performance liquid chromatography (UPLC and together with HPLC, referred to as LC) and mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products and comprehensive post-warranty service plans. The Company designs, manufactures, sells and services thermal analysis, rheometry and calorimetry instruments through its TA Instruments (TA) product line. The Company is also a developer and supplier of advanced software-based products that interface with the Company’s instruments, as well as other manufacturers’ instruments.

What is the price predicton of WAT Stock?

Wall Street analysts forecast WAT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WAT is414.08 USD with a low forecast of 350.00 USD and a high forecast of 480.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Waters Corp (WAT)'s revenue for the last quarter?

Waters Corp revenue for the last quarter amounts to 932.36M USD, increased 6.83

What is Waters Corp (WAT)'s earnings per share (EPS) for the last quarter?

Waters Corp. EPS for the last quarter amounts to 3.76 USD, decreased -2.84

How many employees does Waters Corp (WAT). have?

Waters Corp (WAT) has 7900 emplpoyees as of April 21 2026.

What is Waters Corp (WAT) market cap?

Today WAT has the market capitalization of 32.95B USD.